Photos available upon request
Notes to Editors
Ian Tomlinson - biography
Ian Tomlinson is SVP, Head of Biopharmaceuticals R&D and Worldwide Business Development (WWBD) and sits on GSK's R&D Executive Committee (RADEX).
In his Biopharm R&D role Ian combines the resources and development expertise of a large pharmaceutical company, with the entrepreneurial spirit of a smaller biotech organization, bringing early research, late-stage biopharm development and manufacturing expertise into one organization. This ambitious integrated strategy has taken GSK to a leading position in biopharmaceuticals, deriving over 20 percent of the pipeline from biopharmaceuticals.
In his business development role, Ian has global responsibility for all Pharmaceuticals R&D related business development activities for GSK. His team is committed to finding talent, ideas, and new medicines beyond the wall of GSK's internal Research & Development community.
Ian graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology in Cambridge, where he initially worked on the completion of the sequencing and mapping of all human antibody genes, and latterly on engineering recombinant antibodies. In 2000, together with Sir Gregory Winter, he co-founded Domantis Limited to develop an entirely new class of drugs based on the smallest fragments of antibodies, called Domain Antibodies, or "dAbs". Domantis was acquired by GSK in 2007.
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is the UK's first open innovation bioscience campus, pioneering a unique culture to drive early stage drug discovery and development. It i
|SOURCE Stevenage Bioscience Catalyst|
Copyright©2010 PR Newswire.
All rights reserved